Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

- Cotara(R) Appears Safe and Well Tolerated in Dosimetry and Phase II

Trials, with Some Patients Already Past the Expected Median Average

Survival Time for This Population - - Data From Dosimetry Trial Accepted for Presentation at 2008 ASCO Annual

Meeting -

TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today released an update from two clinical trials assessing its targeted therapy Cotara(R) in the treatment of glioblastoma multiforme (GBM), the most deadly form of brain cancer. The Cotara clinical update covers the first cohort of patients in its dosimetry trial as well as experience to date in an ongoing Phase II safety and efficacy trial. In patients treated in the studies, Cotara appears to be safe and well tolerated, with no dose-limiting adverse events. Patients who are continuing in the trials are being monitored for safety and overall survival, with several surpassing the median expected survival time for relapsed GBM patients. The recent addition of new clinical sites in both the dosimetry and Phase II trials is expected to help accelerate the pace of patient enrollment going forward. The company also announced that data from the first patient cohort in the dosimetry trial has been accepted for presentation at the 2008 ASCO Annual Meeting.

"We are encouraged by early results from these two Cotara clinical studies and look forward to presenting data from the dosimetry trial at the upcoming ASCO Annual Meeting," said Steven W. King, president and CEO of Peregrine. "In v
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive ... and marketing of a series of induction heating equipment. ... series of induction brazing equipments . , According ... brazing refers to the joining of two or ... The manager says that there are fundamental differences in ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Mass. - In a paper that suggests a new strategy ... colleagues report that the influenza virus infection in young mice ... asthma. The same protective effect was achieved by treating young ... ( H. pylori ), a bacterium that colonizes the ...
... 13 (HealthDay News) -- Exposure to a mineral found on ... of a type of lung cancer called mesothelioma, says a ... ash that has been altered by weathering and ground water, ... formations. It looks like transparent, glass-like fibers. Erionite has similar ...
... is available in French . Montreal, December ... significance has become loaded in our society, according to Anthony ... and Anthropology. In his most recent book, Re-Thinking Men: Heroes, ... men are to assume in society. Synnott spent ...
... HealthDay Reporter , FRIDAY, Dec. 10 (HealthDay News) ... type of breast cancer could potentially usher the majority ... breast cancer meeting said Friday. Presenting results from ... Symposium, scientists explained that administering two or more drugs ...
... frustrated by the lack of a meaningful way to screen ... that often progresses with few symptoms until it is too ... most commonly used biomarker used in screening, CA125, are also ... Duke Cancer Institute say that incorporating the latest information about ...
... higher prescription co-payment, especially among older women, is ... adjuvant aromatase inhibitor therapy, a life-saving therapy for women ... Dawn L. Hershman, MD, associate professor of medicine and ... the Herbert Irving Comprehensive Cancer Center at Columbia University, ...
Cached Medicine News:Health News:Study shows how flu infections may prevent asthma 2Health News:Study shows how flu infections may prevent asthma 3Health News:Road Material in N. Dakota May Up Lung Cancer Risk: Study 2Health News:This is a man's world? Yes and no, says new book 2Health News:Certain Drug Combinations May Beat Back Aggressive Breast Cancer 2Health News:Certain Drug Combinations May Beat Back Aggressive Breast Cancer 3Health News:Biological diversity of ovarian cancer lessens value of screening 2Health News:Higher co-payments increase chance of early discontinuation of breast cancer therapy 2
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research ... announced the addition of the "Investment Analysis ... report to their offering. ... investments in the US medical device sector identifies ... equity and venture capital investments, and mergers and ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... following open letter to shareholders from President & ... Dear RXi Shareholders, In ... statements posted on certain social media sites seem ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... , June 21 Ethicon Endo-Surgery, Inc. ... line of surgical devices, the HARMONIC ACE® 45 cm ... the reach of surgeons for minimally invasive procedures involving ... the standard length HARMONIC ACE® device. The additional length ...
... 21 Pfizer Inc. (NYSE: PFE ) announced today ... it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) ... the United States and that it will be voluntarily withdrawing the ... , , , ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: